文献速递免疫规划

新型共刺激分子基因修饰的白血病细胞来源外泌体增强DC疫苗在小鼠模型中的抗白血病疗效

A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
PubMed 文献 · Vaccine · 2024-07-02

研究探讨共刺激分子CD80和CD86基因修饰的白血病细胞来源外泌体(LEX-8086)靶向树突状细胞(DC)疫苗(DCsLEX-8086)在体外和动物模型中的抗白血病免疫应答。结果表明DCsLEX-8086较DCsLEX-null诱导更有效的抗白血病免疫,在预防性和治疗性动物模型中均有效抑制肿瘤生长,并提高肿瘤环境中CD4+ T细胞、CD8+ T细胞和M1巨噬细胞比例,治疗实验中降低Treg比例。作者认为DCsLEX-8086可用于开发新型高效抗白血病疫苗。

要点

  • LEX-8086增强DC成熟和抗原提呈能力。
  • DCsLEX-8086在体外显著激活CD8+ T细胞并增强CTL反应。
  • DCsLEX-8086在预防性和治疗性动物模型中均有效抑制肿瘤生长并发挥抗白血病作用。

核心结论

  • DCsLEX-8086在体内外较DCsLEX-null诱导更有效的抗白血病免疫。
  • DCsLEX-8086可能通过提高肿瘤中CD4+ T细胞、CD8+ T细胞和M1巨噬细胞数量发挥抗肿瘤作用。
  • 作者认为DCsLEX-8086可用于开发新型高效抗白血病疫苗。

研究设计与样本

  • 体外实验:DCs与LEX-8086共孵育产生DCsLEX-8086,采用ELISA、细胞毒性实验和流式细胞术评估抗肿瘤效果。
  • 动物模型:采用流式细胞术评估DCsLEX-8086的免疫调节功能,包括预防性和治疗性动物模型。

主要发现

  • LEX-8086增强DCs的成熟和抗原提呈能力。
  • DCsLEX-8086在体外显著激活CD8+ T细胞并增强CTL反应。
  • DCsLEX-8086在预防性和治疗性动物模型中均有效抑制肿瘤生长并发挥抗白血病作用。
  • DCsLEX-8086在预防性和治疗性实验中均提高肿瘤环境中CD4+ T细胞、CD8+ T细胞和M1巨噬细胞比例。
  • 治疗实验中,DCsLEX-8086对M2巨噬细胞水平无显著差异,但降低肿瘤床中Treg比例。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Leukemia cell-derived exosomes (LEXs), carrying leukemia cell-specific antigens, can serve as a source of antigen for dendritic cell (DC) vaccine loading. However, LEX-targeted DC-based vaccines have demonstrated limited antitumor immune effects in clinical trials, attributed to the low immunogenicity of LEXs and the scant levels of costimulatory molecules on DCs. The costimulatory molecules CD80 and CD86, which are crucial to DC function, play a significant role in enhancing immune efficacy. In this study, we explored the anti-leukemia immune response of costimulatory molecule gene-modified LEX-targeted DCs (LEX-8086) in vitro and in animal models. METHODS: DCs were incubated with LEX-8086 to produce LEX-8086-targeted DCs (DCsLEX-8086). ELISA, cytotoxicity assays and flow cytometry utilized to assess the antitumor efficacy of DCsLEX8086 in vitro. Flow cytometry was used to evaluate the immunomodulatory function of DCsLEX8086 in animal models. RESULTS: Our findings indicated that LEX-8086 enhanced the maturation and antigen-presenting ability of DCs. Immunization with DCsLEX8086 significantly activated CD8+ T cells and boosted the CTL response in vitro. More importantly, DCsLEX-8086 effectively suppressed tumor growth and exerted anti-leukemia effects in both prophylactic and therapeutic animal models. Furthermore, DCsLEX-8086 promoted the proportion of CD4+ T cells, CD8+ T cells and M1 macrophages in the tumor environments both prophylactically and therapeutically. Treatment with DCsLEX-8086 showed no significant difference in the levels of M2 macrophages but decreased the proportion of Tregs within the tumor bed during therapeutic experiments. CONCLUSION: The results suggested that DCsLEX-8086 induces a more effective anti-leukemia immunity compared to DCsLEX-null in vivo and in vitro. DCsLEX-8086 might achieve antitumor effects by elevating the numbers of CD4+ T cells, CD8+ T cells, and M1 macrophages in tumors. Our findings indicate that DCsLEX-8086 could be leveraged to develop a new, highly effective vaccine for anti-leukemia immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang D, Jiang Y, Wang M, et al. A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models. Vaccine. 2024. PMID: 38960787. doi:10.1016/j.vaccine.2024.06.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。